In a conti'olled stucly, inpatient violence was measured cluring placebo, high-potency (halopericlol) and lorv-potency (chlorpromazine or clozapine) neuroleptics. Some patients had a markecl increase in violent behavior rvith the mocleratelv high-dose haloperidol, but not u,ith lou,-potency neuroleptics. The authors cliscuss reasons for the inct'easecl vioience rvith halopericlol, inclucling al<athisia ancl clmg-induced behavioral toxicit.y. Until recently, it rvas u'iclely believecl that the nlentally ill were either less violent or no lnore violent than the general population. Recent findings, holl'ever, suggest that violence is cluite colnlnon in psychiatric hospitals (Yesavage, 1984), ancl consiclerable emphasis is now being placecl on the evaluation (Yesavzrge, 19BB), treatment (F elthous, 1984), and ltrecliction of violence (Mulvey and Liclz, 1984) ancl on the resultant legal ancl ethical issues. Although the potential clrug treatnients for violent behavior are many, neuroleptic drugs are often considered the treatment of choice when violence stems fi'om the psychotic cotrclition (Dubin, 1981; Gunn, 1979). However, there are fell'guicleliries by rvhich the clinician can choose an optitnal neut'oleptic. Accoi'cling to anecdotal reports, some clinicians prefer thioridazine (Itil and Wadacl, 1975), haloperidol (King, 1981), or elopenthixol (Yar-Khan, 1981); others prefer highpotency antipsychotics to low-potency antipsychotics because of a wicler margin of safety when usecl in high dosage (Csernatrskl, g; al., 1985) . In one stucly of 33 aggressive mentaily retarcled people, an unmarketecl l:tenzazepine derivative was notecl to cause less violent behavior than treatrnent u'ith thioriclazine (trlie et al., 1980). However', we are ulta\vare of any sirnilar comparisons of controllecl stndies rvith neuroleptics in schizophrenic patients. We therefore unclertook systematic measurement of violence in patients rvho wel'e to receive both high and lorv-potencv neuroieptics in a controllecl stucly as-sessing the effectiveness of clozapine ancl chlorpromazine in schizophlenic patients who were prospectively cleterminecl to be treatrnent resistant by failure to respond to moclerately high-close haloperidol.
Until recently, it rvas u'iclely believecl that the nlentally ill were either less violent or no lnore violent than the general population. Recent findings, holl'ever, suggest that violence is cluite colnlnon in psychiatric hospitals (Yesavage, 1984) , ancl consiclerable emphasis is now being placecl on the evaluation (Yesavzrge, 19BB), treatment (F elthous, 1984) , and ltrecliction of violence (Mulvey and Liclz, 1984) ancl on the resultant legal ancl ethical issues. Although the potential clrug treatnients for violent behavior are many, neuroleptic drugs are often considered the treatment of choice when violence stems fi'om the psychotic cotrclition (Dubin, 1981; Gunn, 1979) . However, there are fell'guicleliries by rvhich the clinician can choose an optitnal neut'oleptic. Accoi'cling to anecdotal reports, some clinicians prefer thioridazine (Itil and Wadacl, 1975) , haloperidol (King, 1981) , or elopenthixol (Yar-Khan, 1981) ; others prefer highpotency antipsychotics to low-potency antipsychotics because of a wicler margin of safety when usecl in high dosage (Csernatrskl, g; al., 1985) . In one stucly of 33 aggressive mentaily retarcled people, an unmarketecl l:tenzazepine derivative was notecl to cause less violent behavior than treatrnent u'ith thioriclazine (trlie et al., 1980) . However', we are ulta\vare of any sirnilar comparisons of controllecl stndies rvith neuroleptics in schizophrenic patients. We therefore unclertook systematic measurement of violence in patients rvho wel'e to receive both high and lorv-potencv neuroieptics in a controllecl stucly as-sessing the effectiveness of clozapine ancl chlorpromazine in schizophlenic patients who were prospectively cleterminecl to be treatrnent resistant by failure to respond to moclerately high-close haloperidol.
Methods Inclusiott Includeci in the stuclv were 16 male patients rvho rnet DSM-III criteria for schizoplu'enia ancl rvere proven resistant to previous neu'oleptic tleatment efforts. The meari age of the patients u,as 33.3 year-s (range, 25 to 44 years) the mean age at the first hospitalization lvas 18.8 r,'ears (range, 72to 27 years), and the mean numbel of yeal's since the fir'st onset of p.sychosis u'a-s 15.4 (range, 7 to 24). The mean length of the current hospitalization was 83.9 u,eeks (range, 40 to 445), and the mean number of plior psychiatric hospitalizations rvas 10.5 (i'ange, 3 to 25). A retrospective chart, review revealerl that these patients did not have unusual histories of violence.
T reqttrr ert,t R esistatrce Treatment resistance was cleterminecl on the basis of clocr.rnientecl failure to respond aclequately to treatment u'ith at lea-qt three drugs (from tu'o clifferent neuroleptic classes) for durations of 6 rveeks or longer at rninimal daily closes equivalent to approximately 1000 nig/clay of chlorprotnazine during the prececling 5 years. u'ith no periocl of goocl response to antipsychotic therapy during this tinie. At least tr,vo of these three clrug exllerier"rces u,ould have to have occurred in the preceding 2.5 years. Documentation of this inforrnation r.vas clone by s.ysteniatic extraction of medical recorcls for the preceding 5 years by experienced resealch assistants.
E:rclusictrt
Excluclecl fi'orn the study were patients rvho did not exhibit active synrptoms, or patients rvith organic cerebral brain disease or mental retaldation by DSM-III criteria. Also, patients younger than 18, olcler than 55, those actively abusing illicit drugs or alcohol in the 2 rveeks prior to entrance in the study, or those physically ill were exclucled.
Procedure
At the time of the stucly, all patients were part of a larger multicenter clozapine investigation that included a placebo washout period, a high-potency med-ication period (halopericlol), ancl a lorv-potency medication period (clozapine or chlorpromazine). Identified study candidates who hacl given informed consent were administratively transferi'ecl to our research unit ancl then enterecl a 14-day washout periocl receiving oniy placebo capsules (t.i.d.).
Study Periods
The placebo washout u'as follorved by a 6-rveek clinical trial of fixecl-close halopericlol. F or the fir'st 5 days, dosage was increased by 5 mg/day up to 20 mglclay and then stablized for 3 clays. Dosages wel'e then increased by 10 mg/day every three days to a maximuln of 60 mg/day, where they remainecl for the rest of the &week period. This study was follorved by u seconcl placebo period and entry into a 6-rveek double-blind medication trial. Follorving a lveek's titlation periocl, patients received fixecl dosages of either clozapine (900 mg/day) or chlorpromazine (1800 mg/day). Patients given halopericlol and cl'rlorpronrazine also receivecl benztropine (6 mg/day) rvhile on these clrugs.
Clinical Cltange
Clinical change was assesseci on the follorving scerles, completed by research staff at entrance and weekly during the placebo washout periocl: Brief Psychiatric Rating Scale (BPRS; Overall ancl Gorham, 1962), Simpson-Angus Rating Scale for Extrapyramiclal trffects (1970) , and the Abnormal htvoluntary N{ovement Scale (AIMS; Guy, 1976) . Senior nursing staff conrpleted the Lion's Scale of htpatient Violence (Lion et al., 1981) , on a daily basis. The Lion's Scale is basecl on daily observations of a patient's behavior and a rtview of medical records. trpisodes of hostile and aseaultive behavior are extt'actecl ancl quantified into the following subscales: physical (assaults against people, property, or selfl, verbal (assatilts against patients or staffl, and total assaults (r'erbal and physical assaults); the scale is then savecl on a weehlv basis.
Results 0ne-way repeatecl analyses of variance \\rel'e lrerformed on the Lion's suln \\'eekly scores for the three study periods (placebo, halopeliclol, ancl lou' potency medication trials) and the results revealecl a borderline significant effect (F : 2.81, tr < .076). F or the purpose of subsequent analysis of the placebo and trvo drug trial differences, t-tests wet'e choseti. These comparirons yielded significant clifferences bet,,l'een the haloperidol medication and placebo period X * SD: haloperidol,5.25 * 8.3; placebo, 1.94 -r-2.5;t: 3.312, p <.052) and the haloperidol ancl lorv potenclr rns,li.ation periods (low-potency, 1.56 + 2.1; f : 3.68, p < .034). No difference was four-rcl betrveen the lou'-potencv VIOLENT AND I{ONVIOLENT SCHIZOPHRENICIS Verbal assaults Physical assaults Total assaults meclication and placebo period (i :.488). Examination of the clii'ection of the means for the three study periods indicatecl that significantly more violent episodes had occurred during the haloperidol period than during the placebo or low-potency periocl. Inspection of the Liotr's rlata for the haloperidol period revealed the presence of two clistinct patient grollps using a Lion's score of 3 or above for the violenb gt'oup: a violent (.4/ : 7) and nonviolent schizophrenic g:roup (l/ : 9).
Comparisons (i-test; Table 1 ) yielded significant differences between t,he two patient gloups on Lion's total (p <.004), physical (p < .004), and verbal (p < .007) subscales. No clifferences were found between these patients on the Lion's sribscales during the placebo period.
Tlie results of the BPRS are founcl in Table 2 , which provicles means and stanclard deviations for the violent ancl nonviolent schizophrenic patients at the end of the 6-week halopericlol meclication trial. Significant differences were revealecl on the BPRS total (p < .18) and parauoia (p < .0ll) subscales; and borderline significance was reached on the anxiety subscale (p < .I2). Examination of the direction of the BPRS total and subscale means (Table 2) inclicates that the violent schizophrenic patients presented more pathological clinical pictures with prominent paranoid features and reported more subjective stress. No differences were found between these patients on the BPRS subscales during the placebo periocl. The Neurological Rating Scale ancl the scale item "akathisia" were also examinecl at the encl of eacli period. The results for the halopericlol periocl snggestecl fewer extrapyramidal symptoms (X -* SIJ: nonviolent, 7.55 t-5.87; violent, The results of the BPRS at the end of the 6-rveek clinical trial of low-potency meclication are found in Table 3 , which provicles means and standard cleviations for the violent anrl nonviolent schizophrenic patients. Matched /-test comparisorls were used to examine the impact of low-potency meclication on the violent and nonviolent subject.s. In compar:ison rvith the halopericlol period, violent patients significantly improved on the BPRS total (p < .05) ancl paranoia (p < .04) subscale, ancl borcierline significance rvas reachecl on the thought disorcler (p < .06) subscales. Examination of the nonviolent patients' haloperidol us. lowpotency periods failed to reveal significant clifferences on any of the BPRS subscales. Inclucled in the lowpotency gl'oup were three violent ancl four nonviolent clozapine patients ancl four violent ancl five nonviolent chlorprom azine patient s.
Discussion
In this stucly of chronic schizollhrenics, inpatient violence \l'as measurecl chiring placebo, halopericl<-rl, and low-potency neuroleptic drug periocls. Analysis of the results revealed that patients were significantly more violent cluring halopeliclol treatment than cluring the other two periocls. Inspection of the Lion's clata for the haloperidol periorl intiicatecl the presence of two distinct patient groups: violent ancl nonviolent. The violent subgroup also deterioratecl on their BPRS scores during the halopericlol periocl but not cluring the placebo or low-potency periocls. Therefore, it appears that some patients have an increase in violent behavior when given moderately high-dose halopericlol.
There are several possible explanations for these results. Obviously, if patients worsenecl psychiatrically during any treatment periocl, other concomitant or linked behaviors, such as violence, rnight also be expectecl to rvorsen. Hou'ever, these patients did not sholl' an inclease in violence cluring a placebo period, nor clicl tliey have a history of violent behavior. The moclerately high closage of haloperidol (60 mg/day) given in this stucly far exceecls in potency the dosages of both low-potency agents. Because haloperidol appears to display a therapeutic n'inclon' for plasma concentrations (Potkin et al., 1986) , it coulcl be argued that these patienfs may have had high plasma levels that exceeded fhe upper encl of the therapeutic rvindow. Unfortuuately, halopericlol plasma levels \\'ere not ch'ar,vn riuring the drug trial. The high dosage of halo peridol may have inclr"rcecl a form of behavioral toxicity, manifested by an inct'ease in activity and excitement that coulcl conceivabh, Ieacl to an increase in violent behavior. This type of behaviolal abtrormality is not relieved b)' increasing tlie closage of medication and may be relatecl to high blood levels of the neuroleptic (Simpson, 1975) . The present stucly was uncledaken as part of a larger multicetrter clozapine stucly, and preliminar), r'esults indicate that only 47o of haloperidol-treatecl patients irnproved. While these were treirtnrent-resistatrt patients, the small improvement further suggests a lack of i'esponse to moderately highclose halolreridol, ancl one coulcl speculate rvhether a Iower doszrge may have been associated rvith gleater overall irnnrovetnent,.
Bxarnination of the netu'ological rating scale and the scale item akathisia in particuiar suggested that there wel'e nlol'e extrapyt'amidal symptoms in the violent group cluring the halopericlol trial. Because akathisia symlrtorns have been implicatecl in violent behavior in schizophrenic patients (Van Putten, 1975) , it is possible that the liigh extrapy.ramiclal effects of halopericloi may explain the increase in violence, but we must note that the resnlts rvere only a trend and failed to reach significance. It is also possible that the rating scale tlay not reveal subtle inner restlessness, which may lead to sudclen overt and violetrt behavior. Van Putten et al. (1980) argue that al<athisia is related to the plasnla concentration, ancl that at higher concentrations (which may be infen'ecl fi'om the moderately high doses given to our subjects) akathisia could agpp'avate the patients' clinical conclition and predispose to more violent behavior. Aithough patients received benztropine u'ith halopericlol, it has been well-observecl clinically that akatliisia often appears despite prophylacfic antiparkinsonian meclication ancl is often resistant to such treatment.
Low-potency cirugs, such as chlorpromazine and clozapine, are highly sedative ancl thus might be able to suppress violertt behavior in the same way that other seclatives (e.g., benzodiazepines) are useful in violent patients. Hor,rtever, rve dicl not measure a reduction in violence as compared u'ith the plaeebo period, so that a specific effect on violence cloes not appear to be pl'esent. It is possible that, in some patients, lor,v-potency neuroleptics may increase violent behavior via centrzrl nervous systetns disinhibition or their liotential epileptogenic effects. Approximately an equal number of patients rvho become violent on halopericlol were randomly assigrtecl to receive either chlorpromazine or clozapine during the lorv-potency treatrnent periocl. Although the nurnber of patients is too small for statistical atralysis, it appears that both low-potency drugs were equally able to sllppi'ess violence observecl clut'-ing the halopericlol trial. Both clrugs, and clozaltine in particular, have vet'y lou' extraliyramidal effects (Pi and Simpson, 1983) . We found in a controlled stucly that some patients have a marked increase ir-r violence rvhen treatecl with moderately high-dose halopericlol. At this time, ''ve clo not klow rvhetlier such behavior is specific to haloperidol, whether it may have resultecl trom the relatively higher dosage, ol rvhether it may also occur with other high-potency neuroleptics. The reasons for the increased violence may be relatecl to prresumecl exceeding of the therapeutic .,vinclos' .,vith halopericlol with consequent cleclease in antipsychotic effectiveness, 0r may result fi'om subtle extrapyramidal effects of the drug, particularly akathisia (see also Bjdi'nclal et al., 1980) . Further controllecl stuciies are therefore warranted to eluciclate the mechanism of incleasecl violence with halopericlol ancl to ascei'tain whether the effect is unique to halopericlol or is clue to the moclerately large closage used. F tu'ther studies shoulcl attempt to randoniize patients betrveen equivalent closages of both high ancl lou'-potency neuroleptics. Presently, horvever, our results inclicirte that violent behavior may be mor"e fi'ecprent on moclerately highdose halopericlol than on moclerate close. n1 16s,-lrotency neuroleptics.
